117 related articles for article (PubMed ID: 12098594)
1. Pharmacological characterization of YM471, a novel potent vasopressin V(1A) and V(2) receptor antagonist.
Tsukada J; Tahara A; Tomura Y; Wada Ki; Kusayama T; Ishii N; Aoki M; Yatsu T; Uchida W; Taniguchi N; Tanaka A
Eur J Pharmacol; 2002 Jun; 446(1-3):129-38. PubMed ID: 12098594
[TBL] [Abstract][Full Text] [Related]
2. Effects of YM471, a nonpeptide AVP V(1A) and V(2) receptor antagonist, on human AVP receptor subtypes expressed in CHO cells and oxytocin receptors in human uterine smooth muscle cells.
Tsukada J; Tahara A; Tomura Y; Wada Ki ; Kusayama T; Ishii N; Yatsu T; Uchida W; Taniguchi N; Tanaka A
Br J Pharmacol; 2001 Jul; 133(5):746-54. PubMed ID: 11429400
[TBL] [Abstract][Full Text] [Related]
3. Effects of YM218, a nonpeptide vasopressin V1A receptor-selective antagonist, on human vasopressin and oxytocin receptors.
Tahara A; Tsukada J; Tomura Y; Kusayama T; Wada K; Ishii N; Taniguchi N; Suzuki T; Yatsu T; Uchida W; Shibasaki M
Pharmacol Res; 2005 Mar; 51(3):275-81. PubMed ID: 15661579
[TBL] [Abstract][Full Text] [Related]
4. Effect of YM471, a nonpeptide AVP receptor antagonist, on human coronary artery smooth muscle cells.
Tahara A; Tsukada J; Tomura Y; Wada K; Kusayama T; Ishii N; Yatsu T; Uchida W; Taniguchi N; Tanaka A
Peptides; 2002 Oct; 23(10):1809-16. PubMed ID: 12383869
[TBL] [Abstract][Full Text] [Related]
5. Effect of YM471, an orally active non-peptide arginine vasopressin receptor antagonist, on human vascular smooth muscle cells.
Tahara A; Tsukada J; Tomura Y; Kusayama T; Wada K; Ishii N; Yatsu T; Uchida W; Taniguchi N; Tanaka A
J Hypertens; 2002 Sep; 20(9):1807-14. PubMed ID: 12195123
[TBL] [Abstract][Full Text] [Related]
6. In vivo and in vitro characterisation of a nonpeptide vasopressin V(1A) and V(2) receptor antagonist (YM087) in the rat.
Risvanis J; Naitoh M; Johnston CI; Burrell LM
Eur J Pharmacol; 1999 Sep; 381(1):23-30. PubMed ID: 10528130
[TBL] [Abstract][Full Text] [Related]
7. Highly potent and orally active non-peptide arginine vasopressin antagonists for both V1A and V2 receptors: synthesis and pharmacological properties of 4'-[(4,4-difluoro-5-methylidene-2,3,4,5-tetrahydro-1H-1-benzoazepin-1-y l)carbonyl]-2-phenylbenzanilide derivatives.
Shimada Y; Taniguchi N; Matsuhisa A; Sakamoto K; Yatsu T; Tanaka A
Chem Pharm Bull (Tokyo); 2000 Nov; 48(11):1644-51. PubMed ID: 11086891
[TBL] [Abstract][Full Text] [Related]
8. Pharmacologic properties of YM218, a novel, potent, nonpeptide vasopressin V1A receptor-selective antagonist.
Tsukada J; Tahara A; Tomura Y; Kusayama T; Wada K; Ishii N; Taniguchi N; Suzuki T; Yatsu T; Uchida W; Shibasaki M
Vascul Pharmacol; 2005 Jan; 42(2):47-55. PubMed ID: 15722249
[TBL] [Abstract][Full Text] [Related]
9. Effect of the vasopressin receptor antagonist conivaptan in rats with heart failure following myocardial infarction.
Wada K; Tahara A; Arai Y; Aoki M; Tomura Y; Tsukada J; Yatsu T
Eur J Pharmacol; 2002 Aug; 450(2):169-77. PubMed ID: 12206855
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological profile of VP-343, a novel selective vasopressin V2 receptor antagonist, in rats.
Naito A; Ohtake Y; Hasegaw H; Fukaya AY; Kurasawa T; Naito K; Matsukawa H; Oguma T; Ezure Y; Tsuriya Y; Tanaka H; Koike K; Shigenobu K
Biol Pharm Bull; 2000 Feb; 23(2):182-9. PubMed ID: 10706381
[TBL] [Abstract][Full Text] [Related]
11. Vascular and renal effects of vasopressin and its antagonists in conscious rats with chronic myocardial infarction; evidence for receptor shift.
Lankhuizen IM; van Veghel R; Saxena PR; Schoemaker RG
Eur J Pharmacol; 2001 Jul; 423(2-3):195-202. PubMed ID: 11448485
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and pharmacological evaluation of 5-(4-biphenyl)-3-methyl-4-phenyl-1,2,4-triazole derivatives as a novel class of selective antagonists for the human vasopressin V(1A) receptor.
Kakefuda A; Suzuki T; Tobe T; Tsukada J; Tahara A; Sakamoto S; Tsukamoto S
J Med Chem; 2002 Jun; 45(12):2589-98. PubMed ID: 12036368
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological characterization of FE 202158, a novel, potent, selective, and short-acting peptidic vasopressin V1a receptor full agonist for the treatment of vasodilatory hypotension.
Laporte R; Kohan A; Heitzmann J; Wisniewska H; Toy J; La E; Tariga H; Alagarsamy S; Ly B; Dykert J; Qi S; Wisniewski K; Galyean R; Croston G; Schteingart CD; Rivière PJ
J Pharmacol Exp Ther; 2011 Jun; 337(3):786-96. PubMed ID: 21411496
[TBL] [Abstract][Full Text] [Related]
14. Preparation of non-peptide, highly potent and selective antagonists of arginine vasopressin V1A receptor by introduction of alkoxy groups.
Shimada Y; Taniguchi N; Matsuhisa A; Yatsu T; Tahara A; Tanaka A
Chem Pharm Bull (Tokyo); 2003 Sep; 51(9):1075-80. PubMed ID: 12951451
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological profile of YM087, a novel nonpeptide dual vasopressin V1A and V2 receptor antagonist, in dogs.
Yatsu T; Tomura Y; Tahara A; Wada K; Tsukada J; Uchida W; Tanaka A; Takenaka T
Eur J Pharmacol; 1997 Feb; 321(2):225-30. PubMed ID: 9063692
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological characterization of RWJ-676070, a dual vasopressin V(1A)/V(2) receptor antagonist.
Gunnet JW; Wines P; Xiang M; Rybczynski P; Andrade-Gordon P; de Garavilla L; Parry TJ; Cheung WM; Minor L; Demarest KT; Maryanoff BE; Damiano BP
Eur J Pharmacol; 2008 Aug; 590(1-3):333-42. PubMed ID: 18599033
[TBL] [Abstract][Full Text] [Related]
17. In vitro and in vivo pharmacological characterisation of the potent and selective vasopressin V(1A) receptor antagonist 4-[4-(4-Chloro-phenyl)-5-[1,2,3]triazol-2-ylmethyl-4H-[1,2,4]triazol-3-yl]-piperidin-1-yl-(3,5-difluoro-phenyl) methanone (PF-00738245).
Russell R; Doyle R; Turner J; Attkins N; Ramsey S; Weibley L; Bateman L; Bictash M; Neal-Morgan S; Ivarsson M; Pullen N
Eur J Pharmacol; 2011 Nov; 670(2-3):347-55. PubMed ID: 21958878
[TBL] [Abstract][Full Text] [Related]
18. Effects of YM218, a nonpeptide vasopressin V(1A) receptor-selective antagonist, on vasopressin-induced growth responses in human mesangial cells.
Tahara A; Tsukada J; Tomura Y; Momose K; Suzuki T; Yatsu T; Shibasaki M
Eur J Pharmacol; 2006 May; 538(1-3):32-8. PubMed ID: 16678155
[TBL] [Abstract][Full Text] [Related]
19. Aquaretic and hormonal effects of a vasopressin V(2) receptor antagonist after acute and long-term treatment in rats.
Lacour C; Galindo G; Canals F; Segondy D; Cazaubon C; Serradeil-Le Gal C; Roccon A; Nisato D
Eur J Pharmacol; 2000 Apr; 394(1):131-8. PubMed ID: 10771045
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological profile of YM087, a novel potent nonpeptide vasopressin V1A and V2 receptor antagonist, in vitro and in vivo.
Tahara A; Tomura Y; Wada KI; Kusayama T; Tsukada J; Takanashi M; Yatsu T; Uchida W; Tanaka A
J Pharmacol Exp Ther; 1997 Jul; 282(1):301-8. PubMed ID: 9223568
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
